Aralez Pharmaceuticals Stock Price, News & Analysis (TSE:ARZ)

C$1.91 0.11 (6.11 %)
(As of 12/15/2017 04:00 PM ET)
Previous CloseC$1.80
Today's RangeC$1.77 - C$1.91
52-Week RangeC$1.20 - C$6.60
Volume7,250 shs
Average Volume42,016 shs
Market CapitalizationC$93.78 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Aralez Pharmaceuticals (TSE:ARZ)

Aralez Pharmaceuticals logoAralez Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company's products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G. Its development products include YOSPRALA and Bilastine. Fibricor (fenofibric acid) is indicated as a complementary therapy along with diet for the treatment of hypertriglyceridemia, and as a complementary therapy along with diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG) and apolipoprotein B (Apo B). Fibricor is also used to increase high-density lipoprotein (HDL) cholesterol (HDL-C) in patients with hypercholesterolemia or mixed dyslipidemia. Cambia (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug (NSAID).

Receive ARZ News and Ratings via Email

Sign-up to receive the latest news and ratings for ARZ and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Gold
Sub-IndustryN/A
SectorBasic Materials
SymbolTSE:ARZ
CUSIPN/A
Phone+1-905-8761118

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSC($1.68)
Net IncomeN/A
Net Margins-100.42%
Return on Equity-146.16%
Return on Assets-20.43%

Miscellaneous

EmployeesN/A
Outstanding Shares66,886,000

Aralez Pharmaceuticals (TSE:ARZ) Frequently Asked Questions

What is Aralez Pharmaceuticals' stock symbol?

Aralez Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "ARZ."

When will Aralez Pharmaceuticals make its next earnings announcement?

Aralez Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March, 12th 2018. View Earnings Estimates for Aralez Pharmaceuticals.

Who are some of Aralez Pharmaceuticals' key competitors?

Who are Aralez Pharmaceuticals' key executives?

Aralez Pharmaceuticals' management team includes the folowing people:

  • Arthur S. Kirsch, Independent Chairman of the Board (Age 63)
  • Andrew Ian Koven, President, Chief Business Officer (Age 58)
  • Adrian Adams, Chief Executive Officer, Director (Age 64)
  • Michael Kaseta, Head of Finance and Interim Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer (Age 42)
  • Jennifer Lou Armstrong, Executive Vice President - Human Resources and Administration (Age 45)
  • Eric L. Trachtenberg, Chief Compliance Officer, General Counsel, Corporate Secretary (Age 42)
  • Mark A. Glickman, Chief Commercial Officer (Age 50)
  • James Patrick Tursi M.D., Chief Medical Officer (Age 51)
  • Kenneth B. Lee Jr., Lead Independent Director (Age 69)
  • Neal Franklin Fowler, Independent Director (Age 54)

How do I buy Aralez Pharmaceuticals stock?

Shares of Aralez Pharmaceuticals and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Aralez Pharmaceuticals' stock price today?

One share of Aralez Pharmaceuticals stock can currently be purchased for approximately C$1.91.

How big of a company is Aralez Pharmaceuticals?

Aralez Pharmaceuticals has a market capitalization of C$93.78 million.

How can I contact Aralez Pharmaceuticals?

Aralez Pharmaceuticals' mailing address is 7100 West Credit Ave Suite 101, MISSISSAUGA, ON L5N 0E4, Canada. The company can be reached via phone at +1-905-8761118.


MarketBeat Community Rating for Aralez Pharmaceuticals (ARZ)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  30 (Vote Outperform)
Underperform Votes:  41 (Vote Underperform)
Total Votes:  71
MarketBeat's community ratings are surveys of what our community members think about Aralez Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Aralez Pharmaceuticals (TSE:ARZ) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Aralez Pharmaceuticals (TSE:ARZ) Consensus Price Target History

Price Target History for Aralez Pharmaceuticals (TSE:ARZ)

Aralez Pharmaceuticals (TSE:ARZ) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
5/17/2017Chardan CapitalReiterated RatingBuyView Rating Details
4/10/2017Bloom BurtonUpgradeAccumulate -> BuyView Rating Details
(Data available from 12/16/2015 forward)

Earnings

Earnings History for Aralez Pharmaceuticals (TSE:ARZ)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Aralez Pharmaceuticals (TSE:ARZ) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171($0.58)($0.58)($0.58)
Q3 20171($0.63)($0.63)($0.63)
Q4 20171($0.63)($0.63)($0.63)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Aralez Pharmaceuticals (TSE:ARZ)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Aralez Pharmaceuticals (TSE ARZ) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Aralez Pharmaceuticals (TSE:ARZ)

Aralez Pharmaceuticals (TSE ARZ) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/8/2017Arthur S KirschDirectorBuy3,600C$1.45C$5,220.00
10/2/2017James Patrick TursiInsiderSell9,960C$2.50C$24,900.00
7/28/2017Scott J CharlesInsiderSell10,804C$1.25C$13,505.00
6/23/2017Eric TrachtenbergInsiderSell7,720C$1.33C$10,267.60
6/15/2017Arthur S KirschDirectorBuy15,000C$1.15C$17,250.00
6/14/2017Arthur S KirschDirectorBuy50,000C$1.17C$58,500.00
6/5/2017Andrew KovenInsiderSell1,906C$1.28C$2,439.68
3/20/2017Andrew KovenInsiderSell7,025C$2.41C$16,930.25
3/15/2017James Patrick TursiInsiderBuy4,750C$2.11C$10,022.50
3/15/2017Seth RudnickDirectorBuy5,000C$2.37C$11,850.00
(Data available from 1/1/2013 forward)

Headlines

Aralez Pharmaceuticals (TSE ARZ) News Headlines

Source:
DateHeadline
Aralez Pharmaceuticals, Inc. :ARZ-CA: Earnings Analysis: Q3, 2017 By the Numbers : November 14, 2017Aralez Pharmaceuticals, Inc. :ARZ-CA: Earnings Analysis: Q3, 2017 By the Numbers : November 14, 2017
finance.yahoo.com - November 14 at 4:35 PM
ARLZ: Increasing Revenue Projections for 2018ARLZ: Increasing Revenue Projections for 2018
finance.yahoo.com - November 14 at 2:12 AM
Aralez Pharmaceuticals, Inc. – Value Analysis (TORONTO:ARZ) : November 6, 2017Aralez Pharmaceuticals, Inc. – Value Analysis (TORONTO:ARZ) : November 6, 2017
finance.yahoo.com - November 6 at 5:06 PM
Aralez Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARZ-CA : November 3, 2017Aralez Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARZ-CA : November 3, 2017
finance.yahoo.com - November 3 at 9:14 AM
Aralez Pharmaceuticals Inc (ARZ) to Release Quarterly Earnings on ThursdayAralez Pharmaceuticals Inc (ARZ) to Release Quarterly Earnings on Thursday
www.americanbankingnews.com - November 2 at 3:32 AM
Todays Research Reports on Crescita Therapeutics, Centric Health Corporation, Cipher Pharmaceuticals and Aralez PharmaceuticalsToday's Research Reports on Crescita Therapeutics, Centric Health Corporation, Cipher Pharmaceuticals and Aralez Pharmaceuticals
finance.yahoo.com - October 16 at 4:52 PM
Aralez Pharmaceuticals Inc (ARZ) Insider Sells C$24,900.00 in StockAralez Pharmaceuticals Inc (ARZ) Insider Sells C$24,900.00 in Stock
www.americanbankingnews.com - October 4 at 10:42 PM
Aralez Pharmaceuticals, Inc. :ARZ-CA: Earnings Analysis: Q2, 2017 By the Numbers : August 15, 2017Aralez Pharmaceuticals, Inc. :ARZ-CA: Earnings Analysis: Q2, 2017 By the Numbers : August 15, 2017
finance.yahoo.com - August 15 at 5:03 PM
Todays Research Reports on CanniMed Therapeutics Inc., Aralez Pharmaceuticals Inc., Fennec Pharmaceuticals Inc. and Immunovaccine Inc.Today's Research Reports on CanniMed Therapeutics Inc., Aralez Pharmaceuticals Inc., Fennec Pharmaceuticals Inc. and Immunovaccine Inc.
finance.yahoo.com - August 8 at 3:55 PM
Aralez Pharmaceuticals, Inc. :ARZ-CA: Earnings Analysis: Q1, 2017 By the Numbers : August 3, 2017Aralez Pharmaceuticals, Inc. :ARZ-CA: Earnings Analysis: Q1, 2017 By the Numbers : August 3, 2017
finance.yahoo.com - August 3 at 10:31 PM
Aralez Pharmaceuticals Inc (TSE:ARZ) Scheduled to Post Quarterly Earnings on WednesdayAralez Pharmaceuticals Inc (TSE:ARZ) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - August 2 at 7:36 AM
Insider Selling: Aralez Pharmaceuticals Inc (TSE:ARZ) Insider Sells 10,804 Shares of StockInsider Selling: Aralez Pharmaceuticals Inc (TSE:ARZ) Insider Sells 10,804 Shares of Stock
www.americanbankingnews.com - July 28 at 10:35 PM
Aralez To Report Second Quarter 2017 Financial Results On August 9, 2017Aralez To Report Second Quarter 2017 Financial Results On August 9, 2017
finance.yahoo.com - July 24 at 1:01 PM
Aralez Announces District Court Decision to Uphold VIMOVO (Naproxen/Esomeprazole Magnesium) Patents - PR Newswire (press release)Aralez Announces District Court Decision to Uphold VIMOVO (Naproxen/Esomeprazole Magnesium) Patents - PR Newswire (press release)
www.prnewswire.com - June 27 at 8:48 PM
Form 8-K Aralez Pharmaceuticals For: Jun 27Form 8-K Aralez Pharmaceuticals For: Jun 27
www.streetinsider.com - June 27 at 3:47 PM
Aralez Announces National US Commercial Launch Of Zontivity - PR Newswire (press release)Aralez Announces National US Commercial Launch Of Zontivity - PR Newswire (press release)
www.prnewswire.com - June 7 at 6:36 AM
Aralez Pharmaceuticals Inc. 2017 Q1 - Results - Earnings Call SlidesAralez Pharmaceuticals Inc. 2017 Q1 - Results - Earnings Call Slides
seekingalpha.com - May 11 at 4:05 PM
Aralez Announces Reduction In U.S. Sales Force And Cost Savings Program - PR Newswire (press release)Aralez Announces Reduction In U.S. Sales Force And Cost Savings Program - PR Newswire (press release)
www.prnewswire.com - April 7 at 8:07 AM
Horizon Pharma (HZNP) Granted Additional USPTO Notice of Allowance With Claims Covering VIMOVO Delayed ... - StreetInsider.comHorizon Pharma (HZNP) Granted Additional USPTO Notice of Allowance With Claims Covering VIMOVO Delayed ... - StreetInsider.com
www.streetinsider.com - March 31 at 3:46 PM
Aralez Reports Fourth Quarter And Full-Year 2016 Financial Results - PR Newswire (press release)Aralez Reports Fourth Quarter And Full-Year 2016 Financial Results - PR Newswire (press release)
www.prnewswire.com - March 13 at 3:45 PM
Aralez to Present at the RBC Capital Markets Global Healthcare Conference - PR Newswire (press release)Aralez to Present at the RBC Capital Markets Global Healthcare Conference - PR Newswire (press release)
www.prnewswire.com - February 16 at 3:42 PM
Aralez Provides Update on PBM Formulary Status for Yosprala - PR Newswire (press release)Aralez Provides Update on PBM Formulary Status for Yosprala - PR Newswire (press release)
www.prnewswire.com - December 15 at 3:16 PM
Aralez to Participate at Two Upcoming Healthcare Conferences - PR Newswire (press release)Aralez to Participate at Two Upcoming Healthcare Conferences - PR Newswire (press release)
www.prnewswire.com - November 30 at 9:31 AM
Aralez To Acquire US Rights To AstraZenecas Beta Blocker Toprol-XL For $175 MlnAralez To Acquire US Rights To AstraZeneca's Beta Blocker Toprol-XL For $175 Mln
www.nasdaq.com - October 4 at 3:33 PM
AZ agreement with Aralez for Toprol-XL in USAZ agreement with Aralez for Toprol-XL in US
globenewswire.com - October 4 at 3:33 PM
Aralez Pharmaceuticals Inc (ARLZ) Soars on AstraZeneca DealAralez Pharmaceuticals Inc (ARLZ) Soars on AstraZeneca Deal
investorplace.com - October 4 at 11:01 AM
AstraZeneca cuts Brilinta sales hopes on artery disease failureAstraZeneca cuts Brilinta sales hopes on artery disease failure
uk.finance.yahoo.com - October 4 at 8:23 AM
Aralez Pharmaceuticals Lead Drug Yosprala Approved By The FDAAralez Pharmaceuticals' Lead Drug Yosprala Approved By The FDA
seekingalpha.com - September 16 at 8:39 AM
Why Aralez Pharmaceuticals Inc Jumped Higher TodayWhy Aralez Pharmaceuticals Inc Jumped Higher Today
www.fool.com - August 1 at 4:36 PM

SEC Filings

Aralez Pharmaceuticals (TSE:ARZ) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Aralez Pharmaceuticals (TSE ARZ) Stock Chart for Saturday, December, 16, 2017

Loading chart…

This page was last updated on 12/16/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.